Janssen’s IMBRUVICA®▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström’s Macroglobulinemia
- EMEA Innovative Medicine
- Janssen’s IMBRUVICA®▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström’s Macroglobulinemia
Janssen’s IMBRUVICA®▼(ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenström’s Macroglobulinemia
- X (Twitter)
Copy link